...activity in topical applications (See Cover Story). TARGET/MARKER/PATHWAY: Menaquinone LICENSING STATUS: Patent issued; licensed to Genome Pharmaceuticals...

...declined to disclose details. Evotec previously partnered on antibiotics deals with GPC Biotech AG (formerly Genome Pharmaceuticals Corp. AG...

...broad-spectrum antibiotics based on genomics-derived targets. Genome Pharmaceuticals will provide Evotec with antibacterial targets identified using Genome Pharmaceuticals’...
...at which point they will seek a pharmaceutical partner. Evotec Biosystems AG , Hamburg, Germany Genome Pharmaceuticals Corp. AG...

...pharmaceutical, agricultural and food companies. The program will initially focus on pharmacogenomics and agricultural biotech. Genome Pharmaceuticals...
...and Qiagen GmbH (Hilden, Germany), a subsidiary of Qiagen N.V. (NMarkt:QIA; QGENF, Venlo, the Netherlands). Genome Pharmaceuticals Corp. AG...

...Cytovia Inc., San Diego, Calif. Business: Cancer, Autoimmune/Inflammation, Neurological Appointed: Bernd Seizinger, CEO of Genome Pharmaceuticals Corp. WIR...

...collaborate on new genomic targets to control infections caused by Helicobacter pylori and Chlamydia pneumoniae. Genome Pharmaceuticals...
...develop drugs and diagnostics. The deal is worth up to DM50 million (US$30 million) to Genome Pharmaceuticals...
...milestones. In the first stage of the five-year alliance, three projects will be funded at Genome Pharmaceuticals...

...targets expressed during the activation of T helper (Th) cells using the company's genomics technology. Genome Pharmaceuticals...